Skip to content
Review Open access

Temporal trends in small-cell lung cancer trials registered on ClinicalTrials.gov: a cross-sectional analysis (1996–2025)

Aug 2026 · Journal of Thoracic Disease · Vol 18, pp. 939-939 · 0 citations · 6 references
Medicine

Abstract

Background Small-cell lung cancer (SCLC) has undergone important therapeutic advances in recent years, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed disease. Whether the characteristics of registered SCLC clinical trials have evolved in parallel with these advances remains incompletely understood. This study aimed to characterize temporal changes in the design, sponsorship, and geographic distribution of interventional SCLC trials registered on ClinicalTrials.gov between 1996 and 2025. Methods In this cross-sectional study of ClinicalTrials.gov registry records, interventional studies with start dates between January 1, 1996, and December 31, 2025, were identified using the condition terms “Small-Cell Lung Cancer” or “SCLC”. Two oncologists independently screened eligible records according to predefined inclusion and exclusion criteria, with disagreements resolved by a third reviewer. Trial characteristics, including phase, enrollment size, masking, allocation, funding source, geographic participation, and recruitment status, were extracted. Categorical variables were summarized descriptively and compared across six 5-year start-year intervals using Pearson χ2 or Fisher’s exact tests, as appropriate. The Cochran-Armitage trend test was used to evaluate temporal trends in industry sponsorship. Results A total of 825 interventional SCLC trials were included, of which 97.7% evaluated therapeutic interventions. Phase 2 studies predominated (55.7%), 48.4% enrolled fewer than 50 participants, and 91.5% were open-label. Among trials reporting allocation, 69.0% were randomized. Trial activity was concentrated in the United States and China and increased markedly after 2016, with 63.3% of all included trials initiated between 2016 and 2025. Although non-industry funding remained the most common overall, the proportion of industry-sponsored trials increased significantly over time, from 10.3% during 1996–2000 to 37.8% during 2021–2025 (trend P<0.0001). Conclusions Registered SCLC clinical trial activity has expanded substantially during the past decade, reflecting renewed therapeutic development in this disease. Nevertheless, the trial portfolio remains dominated by early- and mid-phase, open-label studies with relatively small enrollment. These findings highlight the need for larger, internationally collaborative, confirmatory trials and more robust evidence generation to translate emerging therapeutic advances into improved outcomes for patients with SCLC.

Read PDF

Similar papers

Review Open access Oct 2026

Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non-Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations.

INTRODUCTION For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. However, real-world data describing tre...

D. Owen, Martin Sebastian, H. Kenmotsu et al. · 0 citations
Review Open access Sep 2026

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.

This real-world analysis shows poor outcomes in patients with progressing ES-SCLC, reflected by both short median PFS and duration of second-line treatment, along with high rates of treatment discontinuation due to progression, highlighting the urgent need for more effective and tolerable treatment options.

Daniel Moser, A. Lang-Stöberl, H. Fabikan et al. · 0 citations
Review Open access Aug 2026

Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov—Based Narrative Review with a Scoping Approach

Background: Pancreatic adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. However, rapid expansion of biomarker-directed therapies, immunotherapy, and novel treatment modalities has created an increasingly complex clinical trial landscape...

Laura Radoš, Sara Matulić Čubranić, M. Golčić et al. · 0 citations
Review Open access Aug 2026

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies

Background The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation is no longer an “elusive” target, having become an important therapeutic target in non-small cell lung cancer (NSCLC). The approvals of sotorasib and adagrasib have significantly altered the second-line treatment algorithm. This systemat...

Julia Piekarz, Natalia Picheta, Jakub Pobideł et al. · 0 citations
Open access Sep 2026

Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset

Background Early treatment discontinuation (ETD) is common in cancer treatment but understudied. We sought to identify clinical and treatment-related factors associated with ETD in a real-world cohort of patients with non-small-cell lung cancer (NSCLC). Patients and methods We analyzed lines of therapy (LoTs) including...

D. Hamze, S. Mishra, A. Mohsin et al. · 0 citations
Review Sep 2026

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

These results show that pembrolizumab is a highly active agent in ccRCC and nccRCC and insights from the comprehensive analysis of RCC tumor molecular components and ctDNA may facilitate progress toward effective, biomarker-driven precision treatment in advanced RCC.

D. McDermott, S. Signoretti, J. Lee et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.